A phase 2, multicenter, randomized, double-blind, placebo controlled parallel-group study evaluating the efficacy and safety of golimumab administered subcutaneously in symptomatic subjects with severe, persistent asthma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2015
At a glance
- Drugs Golimumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Centocor
- 24 Jul 2008 Status changed from initiated to withdrawn prior to recruitment (information from ClinicalTrials.gov).
- 02 Jun 2008 New trial record.